Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dara BioSciences has reported positive results of Phase II trial to test the safety and efficacy of KRN5500 in the treatment of neuropathic pain in cancer patients.
Subscribe to our email newsletter
KRN5500 is a non-narcotic, non-opioid, analgesic agent produced by Streptomyces alanosinicus.
According to the Phase II, double-blind, placebo-controlled, randomized, dose escalation study, KRN5500 showed significant improvement in the relief of neuropathic pain as compared to placebo.
About 50% of KRN5500 patients achieved greater than or equal to 30% improvement in pain intensity compared to 14% of placebo patients.
The data has been published in the Journal of Pain and Symptom Management.